Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

HIV/HCV prevalence and the retention paradox in marginalized populations in Madrid (2019-2023): A large-scale cross-sectional study.

  • Valencia, Jorge
  • Ryan, Pablo
  • Codina Márquez, Helena
  • Cuevas, Guillermo
  • Manzano, Samuel
  • Estévez, Samuel
  • Martinez, Isidoro
  • Sepulveda-Crespo, Daniel
  • Resino, Salvador
Objectives: Marginalized urban populations experience a high burden of HIV and HCV. We assessed the prevalence and risk factors for both infections and characterized the care cascades in a cohort of vulnerable individuals in Madrid, Spain. Methods: We conducted a cross-sectional study (2019-2023) of 4582 individuals via mobile units in high-risk hotspots, offering integrated rapid HIV/HCV testing with point-of-care HCV-RNA confirmation. Multivariable logistic regression identified independent HIV risk factors. Results: HIV prevalence was 6.3% (95% CI: 5.6-7.0). Among people with HIV (PWH), 17.0% of known cases were not receiving antiretroviral therapy; PrEP uptake was zero among HIV-negative individuals. A history of injecting drug use was the primary HIV risk factor (adjusted odds ratio[aOR] 6.6; 95% CI: 4.6-9.5), followed by age >50 years, Spanish origin, and alcohol/benzodiazepine misuse (all P < 0.05). Active HCV prevalence was 5.5% (95% CI: 4.9-6.2); 15.7% in PWH vs 4.8% in people without HIV (P < 0.001). Among confirmed cases, HCV linkage (≥95.2%) and treatment (≥88.6%) were high; however, 16.8% of all antibody-positive individuals (23.2% among PWH) missed confirmatory RNA testing. Conclusions: HIV and HCV remain prevalent, characterized by discontinuities in retention rather than diagnosis. Integrated, low-threshold strategies combining harm reduction with social support are required to address this syndemic.
Repisalud
Publicación Artículo científico (JournalArticle)

Persistent Low Anti-HIV Neutralizing Antibody Titers in HIV/HCV Coinfection Despite HCV Cure: A 5-Year Longitudinal Analysis.

  • Sepulveda-Crespo, Daniel
  • Sánchez-Merino, Víctor
  • Amigot-Sánchez, Rafael
  • Rubio-Pérez, Almudena
  • Díez, Cristina
  • Hontañón, Víctor
  • Berenguer, Juan
  • González-García, Juan
  • García, Felipe
  • Martinez, Isidoro
  • Yuste, Eloísa
  • Resino, Salvador
Background: Anti-HIV neutralizing antibodies (anti-HIV-nAbs) play a critical role in the immune defense against HIV by preventing viral entry and limiting replication. This study longitudinally evaluated the titers and variability of anti-HIV-nAbs in individuals coinfected with HIV and HCV. Samples were collected at three time points: before starting HCV treatment, one year after completion, and five years post-treatment. Methods: A retrospective analysis was conducted on 71 HIV/HCV-coinfected patients who achieved a sustained virologic response following antiviral therapy for HCV. A control group of 41 HIV-monoinfected individuals was also included. Anti-HIV-nAb titers were evaluated by HIV neutralization assays using a panel of six recombinant HIV viruses representing multiple genetic subtypes. Generalized Linear Mixed Models and Generalized Linear Models were used for statistical analysis. p-values were adjusted using the Benjamini-Hochberg procedure (q-value). Results: HIV-neutralizing antibody responses in HIV/HCV-coinfected individuals remained stable over five years following HCV therapy without significant changes (q-value > 0.05). The mean neutralization scores remained stable, with baseline scores of 6.1 (95% CI: 5.4-6.7), 6.2 (95% CI: 5.5-6.8) at one year post-HCV therapy, and 6.0 (95% CI: 5.3-6.7) at five years post-HCV therapy. HIV/HCV-coinfected individuals consistently showed lower neutralization scores compared to the control group throughout the follow-up (q-value < 0.05). Regression analyses adjusted for age, gender, nadir CD4+, and baseline CD4+ counts confirmed that the observed differences between HIV-monoinfected and HIV/HCV-coinfected individuals persisted (q-value < 0.05) at both the baseline and after HCV therapy completion. Conclusions: Successful HCV eradication in HIV/HCV-coinfected individuals did not normalize anti-HIV-nAb titers, which remained consistently lower than those in HIV-monoinfected controls over five years.
Repisalud
Publicación Artículo científico (JournalArticle)

Dengue nanosensors: a roadmap for clinical viability.

  • Codina Márquez, Helena
  • Quero-Delgado, Marta
  • Gómez, Rafael
  • Resino, Salvador
  • Martinez, Isidoro
  • Sepulveda-Crespo, Daniel
Dengue nanosensors promise much but have failed in clinical application. This paradox stems from a focus on record sensitivity over real-world robustness. We propose a paradigm shift from materials discovery to product engineering, providing a translational roadmap to guide viable diagnostics from the lab bench to the patient.
Repisalud
Publicación Artículo científico (JournalArticle)

Trends of non-lethal intentional self-harm and suicide in Spain 2018–2023: a nationwide registry-based study

  • Lopez-Cuadrado, Teresa
  • Mortier, Philippe
  • Alonso, Jordi
  • Martínez-Alés, Gonzalo
Background: Monitoring suicide and non-lethal intentional self-harm (NLISH) is critical for prevention efforts. We analysed trends in NLISH and suicide in Spain (2018–2023), including related demographic and clinical factors. Methods: Nationwide population-based study including all NLISH hospitalisations (from health registries) and suicides (from national mortality data) in Spain between 2018 and 2023. We first examined the sociodemographic characteristics and method used for both outcomes, and the clinical characteristics of NLISH hospitalisations. Then, we evaluated annual and monthly trends in NLISH and suicide rates overall and by sex and age group using Joinpoint regression. Findings: Between 2018 and 2023, we identified 73,692 NLISH hospitalisations and 23,496 suicides in Spain, averaging 12,282 and 3916 annually, respectively. NLISH hospitalisations were more common among women (n = 44,304; 60·1%), and suicides among men (n = 17,471; 74·4%). Youth aged 10–24 accounted for 17,915 (24·3%) NLISH hospitalisations but only 1125 (4·8%) suicides; conversely, individuals aged ≥65 represented 7327 (31·2%) suicides but only 9410 (12·8%) NLISH hospitalisations. The leading methods were drug poisoning for NLISH (n = 50,643; 68·7%) and hanging for suicide (n = 10,810; 46·0%). From 2018 to 2023, NLISH rates rose annually by 8·0% (95% CI: 1·5, 15·9), especially among young women shortly after the 2020 initial pandemic outbreak. Suicide rates rose 2·6% annually (95% CI: 0·6, 4·8), especially among young women and middle-aged men. Interpretation: Non-lethal self-harm is rising in Spain, especially among young women. Suicide shows smaller but significant increases. Urgent, age- and gender-sensitive strategies are needed to address all suicidal behaviour and ensure timely mental health care.
Repisalud
Publicación Artículo científico (JournalArticle)

Determining and characterizing circulating nucleosomes in advanced cancer with electrochemical biosensors assisted by magnetic supports and proteomic technologies.

  • Tejerina-Miranda, Sandra
  • Carral-Ibarra, Elisa
  • Gamella, Maria
  • Montero-Calle, Ana Maria
  • Pedrero, María
  • Pingarrón, José M
  • Barderas Manchado, Rodrigo
  • Campuzano, Susana
Measuring and monitoring plasma nucleosomes (small fragments of chromosomes released into the blood during cell death), and their proteomic profiles is a promising approach for improved early detection, diagnosis, and prognosis of cancer diseases as well as for disease and therapy follow-up, contributing to more personalized and effective cancer care. Early detection is imperative in colorectal cancer (CRC), as it has been proven to significantly improve patient outcomes. Indeed, in CRC, blood circulating nucleosome levels and their histone alterations have been correlated with tumor stage and the presence of metastasis. Moreover, they constitute promising markers for CRC monitoring and prognosis in a minimally invasive way. The current technologies used for their detection suffer from notable drawbacks such as non-selective identification and quantification of unknown cancer-relevant proteomic trademarks, expensive procedures, and variable results related to staff experience. Taking advantage of the sensitive, fast, cost-effective, and reliable methodologies that electroanalytical technologies offer for the determination of multilevel biomarkers in liquid biopsies, we report in this paper the first electrochemical immunoplatform for the isolation and determination of circulating nucleosomes in plasma using an anti-H3.1 histone variant, integrated with proteomics insights to confirm nucleosomes isolation and identify associated proteins with potential as CRC biomarkers. The developed bioplatform was used to analyze 0.5 μg of nuclear extracts from CRC cells with different metastatic potential as well as 1/5 diluted plasma samples, demonstrating the suitability to effectively discriminate CRC patients in advanced stages from healthy individuals through liquid biopsy.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Diagnostic performance of dried blood spot hepatitis C virus core antigen testing for hepatitis C screening: A systematic review and meta-analysis.

  • Treviño-Nakoura, Ana
  • Sepulveda-Crespo, Daniel
  • Bellon, José M
  • Codina, Helena
  • Amigot-Sánchez, Rafael
  • Quero-Delgado, Marta
  • Ryan, Pablo
  • Martinez, Isidoro
  • Resino, Salvador
Dried blood spot (DBS) sampling is increasingly used for hepatitis C virus (HCV) screening. HCVcAg testing offers a faster and more streamlined approach to diagnosing HCV infection. We conducted a systematic review and meta-analysis to assess the diagnostic performance of the Abbott ARCHITECT HCV Ag assay for screening active HCV infection using DBS samples. Eight studies (n = 1229) were selected among all published studies available up to October 4, 2024, in different databases with a search strategy registered (PROSPERO: CRD42022363975). The gold standard method was the HCV PCR test. Data were analyzed using the MIDAS module in STATA with a random effects model. Combined diagnostic accuracy measures were as follows: sensitivity 85%, specificity 100%, positive likelihood ratio (PLR) 233.1, negative likelihood ratio (NLR) 0.15, and summary receiver operating characteristic (SROC) 0.99. Likelihood ratios and Fagan's nomogram suggested that the HCVcAg assay with DBS samples can confirm or rule out active HCV infection with over 92% accuracy in high-prevalence settings (≥5%). However, in low-prevalence settings (≤1%), a confirmatory test must be required for positive results. The ability of the test to identify people without HCV infection was high regardless of HCV prevalence, with an error rate of less than 3%. This meta-analysis is subject to limitations, particularly due to the number of included studies and significant heterogeneity among them. HCV screening using the Abbott ARCHITECT HCV Ag assay with DBS samples showed excellent diagnostic performance, but its external validity may be limited when HCV prevalence is low (≤1%).
Repisalud
Publicación Artículo científico (JournalArticle)

Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023.

  • Ryan, Pablo
  • Valencia, Jorge
  • Pérez-García, Felipe
  • Quero-Delgado, Marta
  • Cuevas, Guillermo
  • Manzano, Samuel
  • Estévez, Samuel
  • Martinez, Isidoro
  • Sepulveda-Crespo, Daniel
  • Resino, Salvador
Background: Hepatitis C virus (HCV) microelimination among at-risk migrants supports global elimination goals.AIMTo evaluate risk factors, prevalence and trends of active HCV infection among at-risk migrants screened for HCV in Madrid from 2019-23. Methods: At-risk migrants (born outside Spain, living in country < 10 years regardless of legal status), were screened for HCV via mobile units with rapid antibody testing, and confirmed by RNA testing. Recruitment of this convenience sample focused on migrant centres, shelters, harm reduction centres and social service sites. Primary outcome was active HCV prevalence. Risk factors analysed included origin, alcohol use, no stable income, drug use and sexual behaviour. Data were analysed using general linear models with negative binomial distribution and p values adjusted for multiple comparisons (q values). Results: TSAmong 2,288 migrants, 6.5% (149/2,288) had anti-HCV antibodies, 47.0% (70/149) of whom tested positive for HCV-RNA; 81.4% (57/70) began antiviral therapy. Overall prevalence of active HCV infection was 3.1% (70/2,288). Injection drug use (non-active vs never used (aIRR: 7.3; 95% CI: 2.7-12.7) and active (aIRR: 14.7; 95% CI: 6.7-32.1)), European origin (vs non-European; aIRR: 5.8; 95% CI:  2.7-12.7) and alcohol misuse (vs no misuse; aIRR: 1.8; 95% CI: 1.1-2.9) were main risk factors. Prevalence showed no significant change during 2019-23 in the overall population and across risk groups. Conclusion: At-risk migrants screened in Madrid had a high prevalence of active HCV infection. This is higher than reported estimates for the general Spanish population and supports the need to enhance targeted HCV prevention, screening and treatment strategies among migrant populations.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Advances in Nanotechnology-Enabled Optical Biosensors for Dengue Virus Detection: A Systematic Review.

  • Quero-Delgado, Marta
  • Codina Márquez, Helena
  • Gómez, Rafael
  • Terán, Francisco José
  • Muñoz-Fernández, M A
  • Jiménez, José Luis
  • Resino, Salvador
  • Sepulveda-Crespo, Daniel
  • Martinez, Isidoro
The dramatic surge in dengue cases in early 2024, endangering half the global population, urgently necessitates faster diagnostic methods. Nanotechnology-enabled optical biosensors offer a promising avenue, leveraging nanomaterial properties for highly sensitive detection of dengue virus (DENV), potentially surpassing conventional techniques in terms of simplicity, speed, and cost-effectiveness. This systematic review analyzes recent advancements in these biosensors for DENV diagnosis. Following PRISMA 2020 guidelines, we systematically searched PubMed, Embase, Scopus, Web of Science, and Cochrane Library databases (2010-June 1, 2025; OSF: https://osf.io/3gmey/). The methodological quality of the 98 included studies was assessed using a modified CASP checklist. Diverse nanotechnology-based optical biosensors were identified. SPR (36.7%) was the most common transducer, followed by fluorescence (24.5%), colorimetry (15.3%), and SERS (8.2%). Gold-based nanomaterials (35.7%) were most frequently employed, with silver nanomaterials (15.3%), quantum dots (15.3%), and graphene-based materials (15.3%) also showing promise. DENV NS1 protein was the primary target analyte (21.4%). Importantly, almost half of the studies (44.9%) used clinically relevant human samples. While many optical biosensors show promise, challenges hinder their demonstration of the true potential for point-of-care use in their current format; however, they offer high specificity and faster results, laying a strong foundation for cost-effective clinical diagnostics. Nanotechnology-driven optical biosensors offer a transformative approach for DENV detection. Advances in computational design and green synthesis of novel nanomaterials are key to addressing stability and field-deployment challenges. These innovations are crucial for developing robust, sensitive, and user-friendly tools to manage dengue and improve patient outcomes globally.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bat-Associated Hemotropic Mycoplasmas in Immunosuppressed Children, Spain, 2024

  • Esperón, Fernando
  • Martín-Maldonado, Bárbara
  • Iglesias, Irene
  • Neves, Elena
  • Seri, Eleonora
  • García Sánchez, Paula
  • Morillas-Mingorance, Ángel
  • Méndez-Echevarría, Ana
All materials published in Emerging Infectious Diseases, including text, figures, tables, and photographs, are in the public domain and can be reprinted or used without permission with proper citation. All content is freely available without charge to the user or their institution. In accordance with the Budapest Open Access InitiativeExternal Link definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. Because the journal is in the public domain, its usage policy also conforms to conditions set forth by Creative CommonsExternal Link., We report the detection of hemotropic mycoplasmas in 4 immunosuppressed pediatric patients in Spain: 2 solid organ transplant recipients, 1 hematopoietic stem cell transplant recipient, and 1 cancer patient. Sequences were 100% identical to a strain previously identified in Miniopterus schreibersii bats, which raises concerns about unnoticed zoonotic transmission., This study was supported by the Health Institute Carlos III, Fondo de Investigaciones Sanitarias-Spanish Health Research Fund (grant no. PI23CIII/00917)., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

Magneto-controlled electrochemical immunosensing platform to assess the senescence-associated GDF-15 marker in colorectal cancer

  • Tejerina Miranda, Sandra
  • Pérez Ginés, Víctor
  • Torrente Rodríguez, Rebeca Magnolia
  • Pedrero Muñoz, María
  • Montero Calle, Ana
  • Pingarrón Carrazón, José Manuel
  • Barderas Manchado, Rodrigo
  • Campuzano Ruiz, Susana
In this study, we report a novel electrochemical immunoplatform using magnetic micro-supports and screen-printed carbon electrodes (SPCEs), overcoming limitations of the methods reported to date, for the rapid and sensitive determination of GDF-15, a molecular marker associated with cellular senescence in aging and cancer development and prognosis. The immunoplatform incorporated a sandwich-type configuration with specific capture and biotinylated-detection antibodies and used a streptavidin–peroxidase (strep–HRP) enzymatic conjugate as label. After magnetic capturing the micro-supports with the sandwich HRP-labeled immunocomplexes onto the surface of a SPCE, the change in cathodic current was quantified in the presence of H2O2 and hydroquinone (HQ), showing a direct correlation with the GDF-15 concentration. The proposed bioplatform exhibited attractive performance characteristics, including a good reproducibility (RSD 4.3%), and a wide linear concentration dynamic range from 140 to 10 000 pg mL−1 with a low limit of detection (LOD) of 42 pg mL−1 for GDF-15 standards in buffered solutions. The selectivity of the developed method and the storage stability of the capturing immunoconjugates were noteworthy. Indeed, the immunoconjugates showed a reliable performance for over 28 days when stored in a refrigerator. The immunoplatform was applied to a cohort of 19 plasma samples representing the different stages of colorectal cancer (CRC). The method allowed efficient discrimination between healthy individuals and CRC patients, particularly those in advanced stages, within a rapid 75-minute timeframe. The immunoplatform also presents substantial advantages in terms of costeffectiveness, assay time reduction, and simplicity compared to other available techniques.
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023

  • Ryan Murúa, Pablo
  • Valencia la Rosa, Jorge Antonio
  • Pérez García, Felipe|||0000-0002-4885-4334
  • Quero Delgado, Marta
  • Cuevas, Guillermo
  • Manzano, Samuel
  • Estévez, Samuel
  • Martínez, Isidoro
  • Sepúlveda Crespo, Daniel
  • Resino, Salvador
11 p., Background: Hepatitis C virus (HCV) microelimination among at-risk migrants supports global elimination goals. Aim: To evaluate risk factors, prevalence and trends of active HCV infection among at-risk migrants screened for HCV in Madrid from 2019-23. Methods: At-risk migrants (born outside Spain, living in country < 10 years regardless of legal status), were screened for HCV via mobile units with rapid antibody testing, and confirmed by RNA testing. Recruitment of this convenience sample focused on migrant centres, shelters, harm reduction centres and social service sites. Primary outcome was active HCV prevalence. Risk factors analysed included origin, alcohol use, no stable income, drug use and sexual behaviour. Data were analysed using general linear models with negative binomial distribution and p values adjusted for multiple comparisons (q values). Results: Among 2,288 migrants, 6.5% (149/2,288) had anti-HCV antibodies, 47.0% (70/149) of whom tested positive for HCV-RNA; 81.4% (57/70) began antiviral therapy. Overall prevalence of active HCV infection was 3.1% (70/2,288). Injection drug use (non-active vs never used ((aIRR: 7.3; 95% CI:2.7-12.7) and active (aIRR:14.7; 95% CI:6.7-32.1)), European origin (vs non-European; aIRR:5.8; 95% CI: 2.7-12.7) and alcohol misuse (vs no misuse; aIRR: 1.8; 95% CI: 1.1-2.9) were main risk factors. Prevalence showed no significant change during 2019-23 in the overall population and across risk groups. Conclusion: At-risk migrants screened in Madrid had a high prevalence of active HCV infection. This is higher than reported estimates for the general Spanish population and supports the need to enhance targeted HCV prevention, screening and treatment strategies among migrant populations., Gilead Sciences, Instituto de Salud Carlos III, Asociación Española para el Estudio del Hígado, Consorcio Centro de Investigación Biomédica en Red, Ministerio de Ciencia e Innovación, Unión Europea, Madrid Positivo Association